Paeds · cardiology
Kawasaki disease and coronary complications
Also known as Kawasaki disease · Kawasaki syndrome · Mucocutaneous lymph node syndrome · KD
Fellowship guide to Kawasaki disease and its coronary complications: the febrile infant with conjunctivitis, rash and red cracked lips, the diagnostic criteria for complete and incomplete disease, the 10-day IVIG and aspirin window that prevents aneurysms, the IVIG-resistant child and escalation to infliximab or steroids, coronary artery z-score grading and anti-thrombotic management, the long-term risk of stenosis and myocardial infarction, and the AHA, European SHARE and ANZ consensus positions.
On this page
Study tools
Your progress
Saved on this device.
Practise this topic
Target exams
Red flags
- Kawasaki disease is a treatable emergency — give IVIG 2 g/kg with high-dose aspirin within ten days of fever onset to prevent coronary artery aneurysms, and treat on clinical suspicion in incomplete disease rather than waiting for the full criteria
- Persistent or recrudescent fever 36 to 48 hours after IVIG defines IVIG-resistant disease and marks the children at highest coronary risk — escalate to a second IVIG, infliximab or other adjuncts rather than observing
- An infant under six months with unexplained fever and irritability has incomplete Kawasaki disease until proven otherwise — check inflammatory markers and an echocardiogram even with few clinical features
- A giant coronary aneurysm (z-score over ten, or absolute diameter at least eight millimetres) carries the highest risk of thrombosis, myocardial infarction and sudden death — add anticoagulation and arrange lifelong specialist surveillance
- A child or adolescent with a history of Kawasaki disease and coronary aneurysms who presents with chest pain, syncope or exertional symptoms has myocardial ischaemia or infarction until proven otherwise — Kawasaki disease is a leading cause of acquired heart disease in young people
Life stages
Care settings
Clinical exam formats
Board mappings
- Cardiology
- Acquired heart disease
- Kawasaki disease
- Paediatric Cardiology — Kawasaki disease and coronary aneurysms
- General Paediatrics learning goal — recognise and treat Kawasaki disease within 10 days
- Lifelong coronary surveillance after aneurysm
- Clinical Applications
- Long Cases
- Short Cases
- Communication scenarios
- Cardiology: recognises and manages Kawasaki disease
- Acquired heart disease in childhood
- Lifelong follow-up after coronary aneurysm
- Foundation of Practice (FOP)
- Applied Knowledge in Practice (AKP)
- Clinical
- History
- Communication
- Cardiovascular examination
- General Pediatrics Content Outline — Domain 9: Cardiology
- Subspecialty: Pediatric Cardiology — acquired heart disease
- Patient Care 1: History and Physical Examination
- Patient Care 4: Clinical Reasoning
- Medical Knowledge 1: Clinical Knowledge of Kawasaki disease
- Systems-Based Practice 1: multidisciplinary cardiac and rheumatology care
- Medical Expert
- Collaborator
- Pediatrics: Core EPA — recognise and treat Kawasaki disease
Overview & Definition
Picture the eighteen-month-old who has been hot and miserable for six days, with red sticky-free eyes, a cracked bleeding mouth, an angry widespread rash, and swollen peeling hands that make her scream when you examine them. No single feature is unique to one illness, but together they are Kawasaki disease — and the clock is already running on a ten-day window to protect her coronary arteries. [1]
Kawasaki disease is an acute, febrile, self-limited vasculitis of childhood that preferentially involves medium-sized muscular arteries, with a striking and characteristic tropism for the coronary arteries. It is the leading cause of acquired heart disease in children in high-income countries. First described by Tomisaku Kawasaki in Japan in 1967, it replaces the older term mucocutaneous lymph node syndrome and is now defined by a clinical cluster of features rather than by any single laboratory test. [4]
Three ideas anchor the whole topic for a fellowship candidate. Kawasaki disease is common enough that every general paediatrician will meet it, and its coronary complications are preventable if treated within ten days. It is a clinical diagnosis, so the skill is in pattern recognition and a low threshold to treat incomplete disease. And it is never truly "over" for a child who develops aneurysms — the lesions can regress, but they can also progress to stenosis, thrombosis and myocardial infarction decades later, which is why surveillance is lifelong. [1]
References15ShowHide
- [1]McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation, 2017.PMID 28356445
- [2]Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med, 1986.PMID 2426590
- [3]Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med, 1991.PMID 1709446
- [4]Burns JC, Glodé MP Kawasaki syndrome. Lancet, 2004.PMID 15302199
- [5]Dallaire F, Dahdah N New equations and a critical appraisal of coronary artery Z scores in healthy children. J Am Soc Echocardiogr, 2011.PMID 21074965
- [6]Dionne A, Burns JC, Dahdah N Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis. Pediatrics, 2019.PMID 31048414
- [7]Burns JC, Mason WH, Hauger SB, Janai H, Chen AL, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr, 2005.PMID 15870671
- [8]Burns JC, Roberts SC, Tremoulet AH, Mahle WT, Cuellar TL, et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial. Lancet Child Adolesc Health, 2021.PMID 34715057
- [9]Saundankar J, Yim D, Itotoh B, Payne R, Maslin K, et al. The epidemiology and clinical features of Kawasaki disease in Australia. Pediatrics, 2014.PMID 24685950
- [10]de Graeff N, Groot N, Ozen S, Honold J, Kone-Paut I, et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease - the SHARE initiative. Rheumatology (Oxford), 2019.PMID 30535127
- [11]Harahsheh AS, Dahdah N, Newburger JW, Portman MA, Slee A, et al. Missed or delayed diagnosis of Kawasaki disease during the 2019 novel coronavirus disease (COVID-19) pandemic. J Pediatr, 2020.PMID 32370951
- [12]Ghelani SJ, Baker AL, Friedman K, Tremoulet AH, Shimizu C, et al. Myocardial Infarction in Kawasaki Disease. J Pediatr, 2025.PMID 40368243
- [13]Tsuda E, Hashimoto S Changes in Coronary Aneurysm Diameters After Acute Kawasaki Disease from Infancy to Adolescence. Pediatr Cardiol, 2021.PMID 34132855
- [14]Portman MA, Dahdah NS, Slee A, Berezin S, Walker E, et al. Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial. Pediatrics, 2019.PMID 31048415
- [15]Lee S, Harahsheh AS, Raghuveer G, Hor KN, Altaye M, et al. Spectrum of Coronary Artery Involvement With Multisystem Inflammatory Syndrome in Children Versus Kawasaki Disease. J Am Heart Assoc, 2025.PMID 40265601